(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -0.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Biontech Se's revenue in 2025 is $2,895,894,736.On average, 7 Wall Street analysts forecast BNTX's revenue for 2025 to be $531,536,530,714, with the lowest BNTX revenue forecast at $491,880,155,499, and the highest BNTX revenue forecast at $605,518,329,733. On average, 7 Wall Street analysts forecast BNTX's revenue for 2026 to be $627,068,667,816, with the lowest BNTX revenue forecast at $431,424,310,847, and the highest BNTX revenue forecast at $750,976,632,578.
In 2027, BNTX is forecast to generate $665,573,663,113 in revenue, with the lowest revenue forecast at $481,439,025,817 and the highest revenue forecast at $852,933,028,073.